|
 The drug approval by the U.S. regulator is for treating patients
with a form of prostate cancer that could not be held back by
standard hormone therapy.
The approval was based on results from a late-stage study where the
drug reduced the risk of disease progression or death by 66% when
compared with hormonal anticancer therapies such as enzalutamide or
abiraterone.
Lynparza leads a class of drugs known as PARP inhibitors, which keep
cancer cells damaged by chemotherapy from repairing themselves, and
is a key asset for AstraZeneca with approvals in ovarian, breast and
pancreatic cancers.
[to top of second column] |
The latest approval for the blockbuster cancer drug comes just weeks after it
won broader approval as a treatment for ovarian caner in the United States.
Prostate cancer is the second most common cancer in men, with more than 191,000
new diagnoses expected in the United States in 2020, according to the American
Cancer Society.
(Reporting by Aakash Jagadeesh Babu in Bengaluru; editing by Uttaresh.V and
Rashmi Aich)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
